Condition: Medulloblastoma, Childhood · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.
This description comes directly from the study's public registry record.
GIANPIERO TAMBURRINI, MD · 3349468776 · gianpiero.tamburrini@unicatt.it
MARIA CONCETTA GELOSO, PHD · mariaconcetta.geloso@unicatt.it
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Gemelli Irccs | Roma, ROMA, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06959979